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suppression after non-ablative conditioning for haploidentical
(3/6 and 4/6 MHC matched related donor) blood HCT. 17
patients with poor prognosis hematological malignancies re-
ceived cyclophosphamide (1gm/m2 days -7 and -6) and ﬂudara-
bine (25mg/m2 days -7 through -3) with sirolimus and tacroli-
mus, (both adjusted to 5-15ng/ml) and methotrexate (5mg/m2
days 1,3, 6) immunoprophyllaxis. Tacrolimus was tapered be-
tween days 40-100 in patients without acute GVHD. ATG
30mg/M was also given days -1,1,3, and 5. Median age was 61.
10 patients had acute leukemias, 6 had Non-hodgkins lym-
phoma and one Hodgkins disease. Only 6 patients were in
remission (CR) at the time of transplant, all of the other 11
having multiply pretreated active malignancy at HCT. Donor
cells engrafted stably in all patients (table below). 16/17
achieved 70% donor chimerism by day 30 and 11/13 90% by
day 100. 15/17 patients developed acute (d100) GVHD, but
this was grade 2 in only 4/17. In 1 patient GVHD developed
at day 121 only after discontinuation of both tacrolimus and
sirolimus. To date 2 patients remain alive free of any progres-
sion of malignancy 1216 and 1543 days post HCT. Only one of
these survivors was in CR at HCT, and this individual is now
enjoying a second remission more than 3 years longer than his
ﬁrst. 6 deaths have resulted from GVHD/Infection, while pro-
gressive malignancy (PD) has been the cause of mortality in 8
patients. One patient died of an unrelated cerebrovascular ac-
cident while free of disease or GVHD at 689 days from trans-
plant. We conclude that, while GVHD and transplant related
mortality remain obstacles, sirolimus and non-ablative condi-
tioning allow reliable engraftment of haplodentical donor HCT
with some long term survivors. These ﬁndings were in elderly
and inﬁrm patients with advanced hematological malignancy.
Engraftment of Haploidentical Cells*
D0 D15 D30 D60 D100
Mean Chimerism 0 0.73 0.88 0.94 0.98
Standard Deviation 0 0.38 0.19 0.15 0.05
Whole Blood Chimerism*
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Sema4D (CD100) is a novel 150 kDa protein that belongs to
the semaphorin family and has recently been shown to modulate
autoimmunity. We tested the requirement of CD100 expression
on T cells in regulating allo-immune responses. When alloge-
neic BALB/c stimulators were cultured with responder cells
from either wild type(wt) B6 or CD100 deﬁcient-/-B6, T cells
from the CD100-/-animals showed a ten fold less expansion
than the WT controls(10,800 /- 1,230 vs. 1,600 /- 258 cpm
p0.01). Consistent with the reduced proliferation, CD100-/-
T cells produced less IFN (1890 pg/mL) compared to B6 wt
Tcells (3478pg/mL) (p0.01). Similar reduction in prolifera-
tion and IFN  production was observed using anti-CD100
mAb’s (data not shown). We next determined the in vivo rele-
vance of CD100 expression on T cell allogeneic responses in a
well characterized experimental model of GVHD. We utilized
the B6(H2b) --BALB/c (H2 d) model where the donor and
recipient are mismatched at both major and minor histocom-
patibility antigens. Recipient BALB/c animals were irradiated
with 8Gy and transplanted with 5.0106 million bone marrow
(BM) cells from wtB6 animals together with 0.5 million T cells
from either wtB6 or CD100 -/- donors. Allogeneic recipients
that were injected with CD100 -/- donor Tcells showed signif-
icantly reduced mortality, less clinical and GVHD speciﬁc tar-
get organ damage (see table). Similar beneﬁt in the reduction of
GVHD was observed with anti-CD100 mAb treatment into the
recipients. When BALB/c recipient mice were challenged with
the P815 (H2 d) murine mastocytoma cell line and received wt
or CD100-/- B6 T cells, there was a signiﬁcant improvement in
the tumor free survival when compared to syngeneic recipients
thus demonstrating preservation of graft-versus-leukemia (90%
survival in allogeneic vs. 0% survival in syngeneic on day 12
post BMT p0.05). We next tested the hypothesis that absence
of CD100 expression on Tcells reduced the function of alloge-
neic APCs. When BALB/c DCs were treated with LPS and
co-cultured with CD100-/- B6 T cells, they secreted less
amounts of TNFa and IL12p70 compared to co-culture with wt
B6 Tcells (table). Use of antiCD100 mAb’s showed similar
results. In conclusion, we demonstrate a novel role for CD100
in regulating in vitro and in vivo allogeneic responses using these
two complementary approaches.
CD100-/- vs Wild Type Tcell in Vitro and in Vivo Outcomes
wt T cells
CD100-/- T
cells p value
OUTCOMES
GvHD Clinical Score
(day  60) 4.6/-0.8 1.8/-0.2 <0.02
Survival (day  60) 55% 100% <0.05
Liver Pathology (day
 60) 17.0/-1.5 9.0/-1.3 <0.01
Skin Pathology (day
 60) 1.5/-0.2 0.8/-0.2 0.02
Intestinal Pathology
(day  60) 7.8/-0.8 4.8/-1.0 0.03
CYTOKINES (pg/
mL)
IFNg serum d14
post BMT 584/-148 286/-97 <0.06
IFNg in vitro 3477/-254 1889/-221 <0.01
DC IL-12p70 in vitro 107/-7 68.5/-2 <0.01
DC TNFa in vitro 5930/-123 4252/-233 <0.01
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AlloPBSCT utilizing NM conditioning is hypothesized to
minimize the toxicity of myeloablative regimens while harness-
ing a potent graft vs malignancy effect. We sought to identify
factors predicting survival in a retrospective analysis of 60 pa-
tients (pts) undergoing alloPBSCT from HLA-matched related
donors between 8/00 and 8/05 at our program. All pts received
90 mg/m2 ﬂudarabine and 200 cGy TBI. GVHD prophylaxis
consisted of CSA/MMF. The median age was 55 years (range
41-66). Male: female was 51:9. All transplants were performed
for hematologic malignancies. The median number of treat-
ments prior to transplant was 4 (range 0-8). The mean cell doses
infused were 8.0 (range 3.5-16.3) x 106 CD34/kg and 28.4
(range 0.9-65.9) x 107 CD3/kg. Among 33 (55%) pts who
became neutropenic, the median time to ANC  500 was 21
days (range 14-49). Primary graft failure occurred in 2 patients.
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